Drug Search Results

Ramatroban

Alternative Names: ramatroban
Latest Update: 2024-03-14
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: TXA2 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Beijing Rundekang Pharmaceutical Technology Co., Ltd.
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ramatroban

Countries in Clinic: India

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: COVID-19|Pneumonia|Respiratory Tract Infections

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
RAMBAN-1	P3	Recruiting	Pneumonia\|Respiratory Tract Infections\|COVID-19	2024-07-01	16%

Recent News Events

Date	Type	Title
03/14/2024	PubMed	Small Molecules for the Treatment of Long-COVID-Related Vascular Damage and Abnormal Blood Clotting: A Patent-Based Appraisal.
02/01/2023	PubMed	The effect of ramatroban on cytokine and thrombotic storms in Covid-19.
01/25/2023	PubMed	Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin.
10/05/2022	News Article	BioLink Life Sciences, Charak Foundation and KARE Biosciences Announce contract for developing a novel treatment of COVID pneumonia and prevention of long COVID

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions